V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 250006619 | 250004684 | 1.9 | 53 | Disease modification (D) | 2014-09-04 | 2014-10-02 | Paclitaxel 7 day | 2 | N | 250029789 | RITUXIMAB |
| 250006620 | 250004685 | 1.71 | 0 | Palliative (P) | 2014-12-24 | 2014-12-24 | INTERFERON | 2 | N | 250029790 | RUXOLITINIB |
| 250006621 | 250004686 | null | 70.5 | Palliative (P) | 2012-10-08 | 2013-11-25 | BUSULFAN | 1 | N | 250029791 | ANAGRELIDE |
| 250006622 | 250004686 | 0 | 79.6 | Disease modification (D) | 2015-06-08 | 2015-06-09 | RUXOLITINIB | 2 | N | 250029791 | PEG INTERFERON |
| 250006623 | 250004686 | 1.55 | 79 | Palliative (P) | null | 2013-06-25 | RUXOLITINIB | null | N | 250029791 | RITUXIMAB |
| 250006624 | 250004687 | null | 67.6 | Palliative (P) | 2016-07-14 | 2016-07-14 | ANAGRELIDE | N | Y | 250029800 | RUXOLITINIB |
| 250006625 | 250004688 | null | 78.2 | Curative (C) | 2015-08-07 | 2015-08-07 | Trial Unspecified | 02 | N | 250029802 | RUXOLITINIB |
| 250006626 | 250004689 | null | null | null | 2018-07-24 | 2018-07-24 | ANAGRELIDE | Y | null | 250029810 | PEG INTERFERON |
| 250006627 | 250004689 | 1.67 | 82.9 | Curative (C) | 2012-12-09 | 2012-12-25 | CHOP R - 21 days | 02 | N | 250029810 | RUXOLITINIB |
| 250006628 | 250004690 | null | null | Palliative (P) | 2013-07-16 | 2013-07-17 | RUXOLITINIB | 01 | N | 250029812 | DA |
| 250006629 | 250004691 | null | null | Curative (C) | 2016-09-20 | 2016-09-28 | RUXOLITINIB | 2 | N | 250029815 | RITUXIMAB |
| 250006630 | 250004692 | null | 51.3 | Palliative (P) | 2014-09-10 | 2014-09-25 | Busulfan Oral | null | null | 250029818 | PEG INTERFERON |
| 250006631 | 250004693 | 0 | 87.1 | Palliative (P) | 2014-03-05 | 2014-03-05 | RUXOLITINIB | N | N | 250029821 | RUXOLITINIB |
| 250006632 | 250004694 | 1.46 | 72.3 | Adjuvant (A) | 2017-11-19 | 2017-11-23 | Trial Unspecified | 01 | N | 250029822 | TRIAL |
| 250006633 | 250004695 | 0 | 73 | Adjuvant (A) | 2017-05-22 | 2017-05-24 | RUXOLITINIB | Y | N | 250029823 | RITUXIMAB |
| 250006634 | 250009574 | null | 75.8 | Disease modification (D) | 2014-07-11 | 2014-07-13 | LENALIDOMIDE | N | N | 250029825 | IMATINIB |
| 250006635 | 250004696 | 1.56 | 87.7 | Palliative (P) | 2014-02-17 | 2014-02-17 | PEG INTERFERON | 02 | N | 250029826 | RUXOLITINIB |
| 250006636 | 250004697 | 0 | 61.8 | Palliative (P) | 2014-10-24 | 2014-10-24 | ANAGRELIDE | N | N | 250029832 | RUXOLITINIB |
| 250006637 | 250004697 | 1.65 | 104.6 | Palliative (P) | 2018-05-07 | 2018-05-10 | RUXOLITINIB | 2 | N | 250029832 | RITUXIMAB |
| 250006638 | 250004697 | 1.75 | 85 | Curative (C) | 2016-12-13 | 2016-12-21 | RUXOLITINIB | 02 | N | 250029832 | AZACITIDINE |
| 250006639 | 250004698 | 1.82 | 84.7 | Curative (C) | 2017-07-22 | 2017-07-23 | RUXOLITINIB | null | N | 250029838 | RUXOLITINIB |
| 250006640 | 250004699 | 1.8 | 56 | Curative (C) | 2014-02-18 | 2014-02-23 | ANAGRELIDE | N | N | 250029840 | IMATINIB |
| 250006641 | 250004700 | 0 | 57 | Disease modification (D) | 2014-10-25 | 2014-11-11 | PEG INTERFERON | N | N | 250029848 | RUXOLITINIB |
| 250006642 | 250004701 | 0 | 77.5 | Curative (C) | 2014-02-24 | 2014-02-24 | Rituximab (Maintenance) | N | N | 250029850 | RUXOLITINIB |
| 250006643 | 250004702 | 0 | null | Palliative (P) | 2015-02-10 | 2015-02-10 | RUXOLITINIB | 02 | N | 250029852 | PEG INTERFERON |
| 250006644 | 250004703 | 1.6 | 65 | Disease modification (D) | 2014-04-08 | 2014-04-13 | RUXOLITINIB | N | N | 250029859 | RUXOLITINIB |
| 250006645 | 250004704 | 1.6 | null | Palliative (P) | 2018-04-11 | 2018-04-11 | AML 18 TRIAL | null | null | 250029863 | RUXOLITINIB |
| 250006646 | 250004705 | 1.67 | 41.2 | Disease modification (D) | 2016-10-09 | 2016-10-16 | RUXOLITINIB | 2 | N | 250029864 | RITUXIMAB |
| 250006647 | 250004705 | 1.74 | 60 | Not known (9) | 2015-08-18 | 2015-08-18 | RUXOLITINIB | 2 | N | 250029864 | CVP R |
| 250006648 | 250004706 | 1.6 | 9.8 | Adjuvant (A) | 2014-06-29 | 2014-06-29 | BENDAMUSTINE + RITUXIMAB | 02 | N | 250029869 | IBRUTINIB |
| 250006649 | 250004707 | 0 | 78.9 | Palliative (P) | 2018-08-05 | 2018-08-05 | Alemtuzumab(INTRAVENOUS) | N | Y | 250029870 | RITUXIMAB |
| 250006650 | 250009577 | 1.67 | 51 | Disease modification (D) | 2014-12-04 | 2014-12-04 | RUXOLITINIB | 2 | N | 250029871 | RITUXIMAB |
| 250006651 | 250004708 | null | null | null | 2015-09-25 | 2015-09-25 | RUXOLITINIB | N | N | 250029874 | IPM |
| 250006652 | 250004709 | null | 65.3 | Palliative (P) | 2017-07-28 | 2017-07-28 | Rituximab | 2 | N | 250029875 | RUXOLITINIB |
| 250006653 | 250004710 | 1.68 | 54.2 | Curative (C) | 2017-10-27 | 2017-10-27 | GALLIUM TRIAL | null | N | 250029876 | IPM |
| 250006654 | 250004711 | null | null | Palliative (P) | 2017-07-10 | 2017-07-11 | Bendamustine+Rituximab (1st Course) | N | null | 250029882 | RUXOLITINIB |
| 250006655 | 250004711 | 1.54 | 73.2 | Palliative (P) | 2017-08-10 | 2017-08-10 | BUSULFAN | 02 | N | 250029882 | RUXOLITINIB |
| 250006656 | 250004712 | 1.75 | 50 | Adjuvant (A) | 2017-08-20 | 2017-08-27 | BUSULFAN | 2 | N | 250029889 | TRIAL |
| 250006657 | 250004713 | null | 81.3 | Adjuvant (A) | 2018-04-11 | 2018-05-25 | RUXOLITINIB | N | N | 250029895 | MIDOSTAURIN |
| 250006658 | 250004714 | null | 62 | Palliative (P) | 2013-03-19 | 2013-03-19 | Capecitabine + Oxaliplatin 21day | 1 | N | 250029898 | TRIAL |
| 250006659 | 250004715 | 1.6 | 75.7 | Palliative (P) | 2016-06-21 | 2016-06-27 | RUXOLITINIB | N | N | 250029902 | BUSULPHAN |
| 250006660 | 250004716 | 1.57 | 73 | Disease modification (D) | 2015-05-03 | 2015-05-31 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | null | N | 250029903 | MELPHALAN |
| 250006661 | 250004716 | null | 68.1 | Curative (C) | 2016-02-29 | 2016-02-29 | FEC 100 | Y | N | 250029903 | TRIAL |
| 250006662 | 250004717 | 1.57 | 54.7 | Palliative (P) | 2017-01-18 | 2017-01-19 | Trial Unspecified | N | N | 250029913 | RUXOLITINIB |
| 250006663 | 250004718 | 1.7 | 59.1 | Adjuvant (A) | 2015-11-17 | 2015-11-19 | FCR Oral - Cycle 1 | Y | N | 250029914 | NILOTINIB |
| 250006664 | 250004719 | 0 | 73 | Neo-adjuvant (N) | null | 2017-06-14 | Rituximab | N | N | 250029915 | RITUXIMAB |
| 250006665 | 250004720 | 1.63 | 72 | Palliative (P) | null | 2014-03-11 | RUXOLITINIB | N | N | 250029917 | TRIAL |
| 250006666 | 250004721 | 1.73 | 110.6 | Palliative (P) | 2015-12-10 | 2015-12-16 | RUXOLITINIB | 99 | N | 250029918 | RUXOLITINIB |
| 250006667 | 250004722 | 1.6 | 75 | Curative (C) | 2013-05-18 | 2013-06-13 | RUXOLITINIB | N | N | 250029920 | DA |
| 250006668 | 250004722 | 1.37 | 100 | Disease modification (D) | 2012-08-17 | 2012-08-17 | DA | 02 | N | 250029920 | RUXOLITINIB |